Skip to main content

Table 1 Baseline characteristics and anti-citrullinated protein antibody (ACPA) reactivities in subgroups of patients with rheumatoid arthritis (RA) and controls

From: The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy

 

All RA

n = 217

Anti-CCP+

n = 178

Anti-CCP-

n = 39

RF+

n = 154

RF-

n = 63

Anti-CCP+/RF+

n = 147

Anti-CCP-/RF-

n = 32

Controls

n = 94

Age, yearsa

51.5 (13.6)

50.8 (13.2)

55.0 (14.9)

51.9 (13.3)

50.8 (14.2)

51.7 (13.6)

55.0 (16.1)

52.1 (9.2)

Femaleb

131 (60)

109 (61)

22 (56)

91 (59)

40 (63)

86 (59)

17 (53)

57 (61)

Ever-smokerb

148 (68)

122 (69)

26 (67)

109 (71)

39 (62)

103 (70)

20 (62)

60 (64)

DASa

3.5 (1.2)

3.4 (1.1)

4.0 (1.3)

3.5 (1.2)

3.5 (1.2)

3.42 (1.1)

3.9 (1.2)

NA

DAS28a

4.4 (1.2)

4.4 (1.2)

4.7 (1.2)

4.5 (1.2)

4.2 (1.3)

4.5 (1.1)

4.5 (1.1)

NA

vdHSS totalc

4.0 [1.5, 8.0]

4.0 [1.5, 7.9]

4.5 [2.0, 10]

4.5 [2.0, 8.0]

3.5 [1.5, 10]

4.5 [2.0, 8.0]

5.5 [1.8, 12.8]

NA

vdHSS erosionc

3.0 [1, 4.5]

3.0 [1, 4.5]

3.0 [1.0, 5.5]

3.0 [1.5, 4.5]

3.0 [1.0, 5.5]

3.0 [1.0, 4.5]

3.0 [1.0, 6.3]

NA

vdHSS JSNc

1.0 [0.0, 3.0]

1.0 [0.0, 3.0]

1.5 [0.0, 5.0]

1.0 [0.0, 3.0]

1.0 [0.0, 3.0]

1.0 [0.0, 3.0]

1.5 [0.0, 6.5]

NA

Ultrasound grey scalec

18 [10, 28]

16 [9, 24]

33 [20, 51]

17 [10, 26]

21 [12, 36]

16 [9, 25]

33 [21, 52]

NA

Ultrasound power Dopplerc

7 [3, 14]

6 [2, 12]

14 [6, 28]

6 [2, 13]

8 [3, 15]

6 [2, 12]

13 [6, 29]

NA

Number of ACPA reactivitiesc

9 [4, 12]

10 [7, 12]

0 [0, 1]

10 [7, 12]

2 [0, 10]

10 [7, 12]

0 [0, 1]

0 [0, 0]

ACPA reactivity status, n (%)

 Fibβ 60-74cit

162 (75)

160 (90)

2 (5)

136 (88)

26 (41)

134 (91)

0 (0)

0 (0)

 Vim 60-75cit

159 (73)

152 (85)

7 (18)

130 (84)

29 (46)

128 (87)

5 (16)

5 (5)

 H4 31-50cit

145 (67)

142 (80)

3 (8)

119 (77)

26 (41)

118 (80)

2 (6)

1 (1)

 CEP-1

140 (65)

137 (77)

3 (8)

117 (76)

23 (37)

115 (78)

1 (3)

1 (1)

 Fil 307-324cit

136 (63)

134 (75)

2 (5)

113 (73)

23 (37)

112 (76)

1 (3)

0 (0)

 Fibα 573cit

123 (57)

121 (68)

2 (5)

99 (64)

24 (38)

99 (67)

2 (6)

0 (0)

 Fibβ 36-52cit

117 (54)

116 (65)

1 (3)

96 (62)

21 (33)

96 (65)

1 (3)

2 (2)

 H3 1-30cit

107 (49)

106 (60)

1 (3)

93 (60)

14 (22)

92 (63)

0 (0)

0 (0)

 H4 14-34cit

105 (48)

103 (58)

2 (5)

90 (58)

15 (24)

88 (60)

0 (0)

3 (3)

 H3 21-44cit

96 (44)

94 (53)

2 (5)

80 (52)

16 (25)

79 (54)

1 (3)

1 (1)

 Fibα 621-635cit

93 (43)

92 (52)

1 (3)

78 (51)

15 (24)

77 (52)

0 (0)

1 (1)

 Vim 2-17cit

88 (41)

87 (49)

1 (3)

80 (52)

8 (13)

79 (54)

0 (0)

0 (0)

 Fibα 36-50cit

79 (36)

79 (44)

0 (0)

67 (44)

12 (19)

67 (46)

0 (0)

0 (0)

 Fibα 591cit

69 (32)

66 (37)

3 (8)

56 (36)

13 (21)

55 (37)

2 (6)

1 (1)

 Fibβ 74cit

66 (30)

60 (34)

6 (15)

54 (35)

12 (19)

51 (35)

3 (9)

3 (3)

 Fibβ 72cit

27 (12)

24 (13)

3 (8)

21 (14)

6 (1)

20 (14)

2 (6)

2 (2)

  1. Abbreviations: RA rheumatoid arthritis; anti-CCP anti-cyclic citrullinated peptide, RF rheumatoid factor, DAS Disease Activity Score, vdHSS van der Heijde modified Sharp score, JSN joint space narrowing, ACPA anti-citrullinated protein antibody, Fib fibrinogen, cit citrullinated, Vim vimentin, H histone, CEP-1 citrullinated enolase peptide-1, Fil filaggrin; numbers referring to amino acid sequence, NA not applicable
  2. aMean (SD)
  3. bNumber (percentage)
  4. cMedian [25, 75 percentile]
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us